BMC Cancer (Mar 2018)

Correction to: Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM

  • Lina Mörén,
  • Richard Perryman,
  • Tim Crook,
  • Julia K. Langer,
  • Kevin Oneill,
  • Nelofer Syed,
  • Henrik Antti

DOI
https://doi.org/10.1186/s12885-018-4128-9
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 1

Abstract

Read online

Abstract In the original publication of this article [1], published on 8 February 2018, it was noticed that the acknowledgement of the source of the drug ADI-PEG20 was missing.